Implementation Initiatives and Partners

Who is Rolling out PrEP Now, How are They Doing it & Who is Funding it

USAID Microbicide Product Introduction Initiative (MPii)

The US Agency for International Development (USAID) is supporting five connected projects focused on introducing and providing access to ARV-based HIV prevention. These projects, which run from 2015-2020, focus on gender-based violence, drug resistance, creating demand, introducing new products, and models for delivering services. For a more detailed look at each of the five MPii projects, click here. And to see Tools & Resources from these projects, click here.

DREAMS Programs

Launched in 2014, the DREAMS Initiative aims to reduce the incidence of HIV by 40 percent among adolescent girls and young women by 2020. It is a collaboration between the US President’s Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates FoundationGirl EffectJohnson & JohnsonGilead Sciences and ViiV Healthcare.

The PEPFAR Scientific Advisory Board has endorsed PrEP and launched a DREAMS Innovation Challenge, to make more resources available for PrEP.

DREAMS is operating in ten countries, five of which have included PrEP for adolescent girls and young women in their country plans to address HIV.

PEPFAR (US President’s Emergency Plan for AIDS Relief)

Working in over 60 countries, PEPFAR has transformed the global HIV/AIDS response by supporting nearly 11.5 million people with antiretroviral treatment, a 50 percent increase since 2014. This is compared with the only 50,000 people who were on treatment in sub-Saharan Africa when PEPFAR began in 2003.

PEPFAR is now supporting rollout of PrEP. Click here to explore quarterly PEPFAR data, including the “number of adults and adolescents who received PrEP”. Click here to view PEPFAR “Country Operational Plans (COPs)” which outline PEPFAR yearly plans, country-by-country. Many COPs include provisions for PrEP.

Bridge to Scale (Jilinde)

The Bridge to Scale, or Jilinde, project is an implementation science initiative that seeks to move oral pre-exposure prophylaxis (PrEP) from research and demonstration settings into a large-scale public health response in Kenya. Over 20,000 people at highest risk of HIV infection will receive oral PrEP, which will be integrated within existing HIV combination prevention services. This project will demonstrate the incredible potential of PrEP and generate evidence that population-level PrEP interventions are feasible and effective in low-and middle-income countries, which bear the brunt of the world’s HIV burden. Bridge to Scale began delivering PrEP in early 2017.

The project functions as a learning laboratory to identify and document the barriers and enablers to PrEP uptake. Ultimately, the project will develop an affordable, effective, sustainable and replicable model for oral PrEP scale-up.

HIV Prevention Market Manager

Through the HIV Prevention Market Manager (PMM) Project, AVAC and CHAI seek to facilitate an efficient and effective rollout of HIV prevention products. The PMM works with partners across the prevention research to rollout spectrum to expand the portfolio of options and ensure appropriate products are available, accessible and used by those who need them most. Learn more.

For resources on end user work to date, click here.

News Spotlight

  • A Daily Pill Can Prevent HIV Infections. Why Don’t More People Use It?

    March 9, 2018

    There’s no question that a simple regimen of a single daily pill can slash HIV infections in people at risk. But although millions of people around the world could benefit, only 200,000 are prescribed PrEP, and 75 percent of them are in the United States. The disparity was the focus of anguished discussions this week at the largest annual US HIV/AIDS conference.

    Read more

  • Mapping PrEP: First ever data on PrEP users across the US

    March 6, 2018

    The Center for AIDS Research at Emory University's Rollins School of Public Health produces interactive online maps with visualized data on different aspects of the US HIV epidemic, and its prevention and treatment response, at This set of maps and statistics focuses on PrEP use nationally and by state from 2012-2016.

    Read more